TUT1 Antibody

What is TUT1 and why is it significant for RNA biology research?

TUT1, also known as Terminal Uridylyl Transferase 1, functions as both a terminal uridylyltransferase and a nuclear poly(A) polymerase. This nucleotidyl transferase specifically adds and removes nucleotides from the 3' end of small nuclear RNAs and select mRNAs, playing a crucial role in RNA processing pathways . TUT1 (also referred to as Star-PAP, PAPD2, or RBM21) specifically catalyzes the uridylylation of U6 snRNA and is essential for cell proliferation, making it a significant target for researchers studying post-transcriptional gene regulation mechanisms . The protein contributes to controlling gene expression and cellular proliferation through its RNA-modifying activities. Understanding TUT1 function is particularly important as it represents a key component in RNA metabolism that impacts numerous downstream cellular processes.

What applications are TUT1 antibodies most commonly used for in research?

TUT1 antibodies are versatile research tools applicable across multiple experimental techniques. Based on validated applications, TUT1 antibodies are primarily used for:

• Western Blotting (WB): For detecting and quantifying TUT1 protein expression in cell and tissue lysates, typically visualized as a band around 93 kDa .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of TUT1 in solution samples .

• Immunohistochemistry (IHC): For visualizing TUT1 localization within tissue sections .

• Immunocytochemistry (ICC): For examining TUT1 distribution within cultured cells .

• Immunofluorescence (IF): For high-resolution visualization of TUT1 localization and co-localization studies with other proteins .

Each application requires specific optimization of antibody concentration, with typical dilutions ranging from 1:50-1:100 for IHC to 1:20000 for ELISA, demonstrating the importance of application-specific protocol adjustments .

How should researchers select the appropriate TUT1 antibody for their specific experiments?

Selecting an appropriate TUT1 antibody requires careful consideration of multiple factors to ensure experimental success:

• Target epitope consideration: Determine whether your experiment requires an antibody targeting the N-terminus, internal region, or specific amino acid sequences (e.g., AA 291-340) of TUT1 . Different epitopes may be more accessible depending on protein conformation or experimental conditions.

• Species reactivity: Verify that the antibody recognizes TUT1 in your experimental species. Available antibodies have varying cross-reactivity with human, mouse, rat, and other species . For example, some antibodies recognize human, mouse, and rat TUT1, while others are human-specific .

• Antibody format: Choose between polyclonal and monoclonal antibodies based on your experimental needs. Polyclonal antibodies typically offer higher sensitivity but potentially lower specificity compared to monoclonal antibodies .

• Validation evidence: Prioritize antibodies with thorough validation data for your specific application. Similar to approaches used for TIA1 antibodies, look for validation methods that include knockout controls to confirm specificity .

• Application compatibility: Ensure the antibody is validated for your specific application (WB, IHC, IF, etc.) as performance can vary significantly between applications .

Researchers should review available technical documentation thoroughly and consider conducting preliminary validation experiments before proceeding with critical studies.

How can researchers optimize Western blot protocols specifically for TUT1 detection?

Optimizing Western blot protocols for TUT1 detection requires careful attention to several technical factors:

• Sample preparation: For optimal TUT1 detection, use RIPA buffer supplemented with protease inhibitors to extract total protein while preserving TUT1 integrity. Nuclear extraction protocols may improve detection since TUT1 is primarily a nuclear protein involved in RNA processing .

• Protein loading and transfer conditions: Load 20-30 μg of total protein per lane and use a 10% SDS-PAGE gel to achieve optimal separation around the 93 kDa region where TUT1 migrates . For efficient transfer of this higher molecular weight protein, employ a wet transfer system with 10% methanol buffer at 30V overnight at 4°C.

• Blocking and antibody conditions: Block membranes with 5% non-fat dry milk in TBST for 1 hour at room temperature. For primary antibody incubation, use TUT1 antibody at a dilution of 1:1000 in 5% BSA/TBST overnight at 4°C . Similar to approaches used for other RNA-binding proteins, thorough washing between antibody incubations (5-6 times for 5 minutes each) helps reduce background .

• Detection system selection: For the most sensitive detection of TUT1, use enhanced chemiluminescence (ECL) systems with extended exposure times (1-5 minutes) as needed, or consider fluorescent secondary antibodies for more precise quantification.

• Controls: Always include positive controls (cell lines known to express TUT1) and negative controls (TUT1 knockout or knockdown samples when available) to validate specificity of detection .

This optimized protocol should yield clear, specific detection of TUT1 with minimal background interference, allowing for reliable quantification and comparative analysis.

What validation methods should be employed to confirm TUT1 antibody specificity?

A comprehensive validation approach for TUT1 antibodies should include multiple complementary methods:

• Knockout/knockdown validation: The gold standard for antibody validation involves comparing signal between wild-type samples and those with TUT1 genetically depleted. This approach, similar to that used for TIA1 antibody validation, provides definitive evidence of specificity . Generate TUT1 knockout cell lines using CRISPR/Cas9 or use siRNA knockdown, then confirm the absence of signal in Western blot, immunofluorescence, or other applications.

• Peptide competition assay: Pre-incubate the TUT1 antibody with excess immunizing peptide (if available) prior to application. Disappearance of the signal indicates specificity for the target epitope .

• Cross-platform validation: Compare results across multiple detection methods (e.g., Western blot vs. immunofluorescence vs. immunoprecipitation) to ensure consistent detection patterns .

• Cross-antibody validation: Compare results using multiple antibodies targeting different epitopes of TUT1. Consistent detection patterns increase confidence in specificity .

• Recombinant protein controls: Test antibody against purified recombinant TUT1 protein to establish detection limits and specificity.

Documentation of these validation experiments is crucial for ensuring reproducible research and should be included in publications using TUT1 antibodies.

What are the critical factors for successful immunoprecipitation of TUT1?

Successful immunoprecipitation of TUT1 requires attention to several critical factors:

• Lysis buffer composition: Use a gentle lysis buffer (e.g., 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS) supplemented with protease inhibitors, phosphatase inhibitors, and RNase inhibitors (if RNA-protein complexes are of interest).

• Antibody selection: Choose TUT1 antibodies specifically validated for immunoprecipitation applications. N-terminal targeting antibodies often perform better for IP as these regions are typically more accessible in the native protein conformation .

• Pre-clearing step: Pre-clear lysates with protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Antibody binding conditions: Incubate pre-cleared lysates with 2-5 μg of TUT1 antibody overnight at 4°C with gentle rotation to preserve protein complexes .

• Washing stringency balance: Perform 4-5 washes with decreasing salt concentrations (starting with 300 mM NaCl and ending with 150 mM NaCl) to remove non-specific interactions while preserving specific TUT1 complexes.

• Elution strategy: For protein interaction studies, use gentle elution with 0.1 M glycine (pH 2.5) followed by immediate neutralization. For downstream RNA analysis, consider crosslinking prior to IP followed by proteinase K digestion to release RNA.

• Controls: Always include IgG control immunoprecipitations and, when possible, TUT1-depleted samples as negative controls .

These optimized conditions will help ensure specific enrichment of TUT1 and its interaction partners for downstream analysis.

How should researchers design experiments to study TUT1's role in RNA processing?

Designing robust experiments to investigate TUT1's role in RNA processing requires a multifaceted approach:

• Loss-of-function studies: Implement CRISPR/Cas9 knockout or siRNA knockdown of TUT1, followed by RNA-seq to identify global changes in RNA processing, particularly focusing on U6 snRNA uridylylation and mRNA poly(A) tail modifications .

• Gain-of-function approaches: Express wild-type or catalytically inactive TUT1 mutants (with mutations in the nucleotidyl transferase domain) to distinguish enzymatic from structural roles.

• Domain-specific analysis: Design experiments with truncated TUT1 variants to determine which protein domains are essential for specific functions in RNA processing. This approach can utilize antibodies targeting different regions of the protein to confirm expression of truncated variants .

• RNA-protein interaction studies: Combine RNA immunoprecipitation (RIP) or CLIP-seq (Crosslinking Immunoprecipitation followed by sequencing) using validated TUT1 antibodies to identify direct RNA targets .

• Temporal analysis: Design pulse-chase experiments to track RNA modifications over time, revealing the kinetics of TUT1-mediated uridylylation or polyadenylation.

• Context-specific studies: Examine TUT1 function under various cellular conditions (e.g., stress, cell cycle phases) to understand context-dependent roles in RNA processing.

• In vitro biochemical assays: Complement cellular studies with purified components to directly assess TUT1's enzymatic activities on defined RNA substrates.

What controls are essential when using TUT1 antibodies for immunofluorescence studies?

Implementing comprehensive controls for TUT1 immunofluorescence studies is critical for generating reliable data:

• Primary antibody specificity controls:

  • Genetic depletion: Compare staining between wild-type and TUT1 knockout/knockdown cells .

  • Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding.

  • Secondary-only control: Omit primary antibody to assess non-specific secondary antibody binding.

• Technical controls:

  • Fixation controls: Compare different fixation methods (PFA vs. methanol) as epitope accessibility may vary with fixation.

  • Permeabilization controls: Test different permeabilization reagents (Triton X-100, saponin) and concentrations.

  • Blocking optimization: Test different blocking reagents (BSA, normal serum, commercial blockers) to minimize background.

• Biological reference controls:

  • Positive control tissues/cells: Include samples known to express TUT1 at high levels.

  • Subcellular localization markers: Co-stain with nuclear markers (e.g., DAPI) to confirm the expected nuclear localization of TUT1 .

  • Treatment-responsive controls: Include samples with conditions known to alter TUT1 expression or localization.

• Quantification controls:

  • Signal intensity calibration: Include fluorescent beads or similar standards when performing quantitative analysis.

  • Threshold controls: Establish objective thresholding criteria for quantification.

By implementing these controls systematically, researchers can confidently interpret TUT1 immunofluorescence data and distinguish true biological phenomena from technical artifacts.

How do different fixation and permeabilization methods affect TUT1 antibody performance?

The choice of fixation and permeabilization methods significantly impacts TUT1 antibody performance in immunostaining applications:

Researchers should conduct systematic optimization experiments comparing these methods before finalizing protocols for critical experiments, as the optimal conditions may vary depending on the specific TUT1 antibody and cellular context.

How should researchers interpret multiple bands in TUT1 Western blots?

Multiple bands in TUT1 Western blots require careful interpretation based on systematic analysis:

• Expected TUT1 patterns:

  • The primary TUT1 band is expected at approximately 93 kDa, corresponding to the full-length protein .

  • Additional bands at ~70 kDa and ~50 kDa may represent alternative splicing variants or post-translational modifications.

• Potential causes and interpretations:

  Band Pattern	Likely Cause	Interpretation Approach
  Multiple close bands (90-95 kDa)	Post-translational modifications (phosphorylation, ubiquitination)	Treat with phosphatases or deubiquitinases to confirm
  Lower molecular weight bands (40-70 kDa)	Proteolytic degradation	Add additional protease inhibitors during sample preparation
  Lower molecular weight bands (consistent pattern)	Alternative splicing variants	Validate with RT-PCR for known TUT1 isoforms
  Higher molecular weight bands (>100 kDa)	Protein complexes resistant to denaturation	Increase SDS concentration or boiling time
  Non-specific bands (variable pattern)	Cross-reactivity	Perform peptide competition or use TUT1-depleted controls

• Validation approaches:

  • Compare patterns across multiple TUT1 antibodies targeting different epitopes .

  • Test TUT1 knockout/knockdown samples to identify which bands disappear (specific) versus persist (non-specific) .

  • Use recombinant TUT1 protein as a positive control to establish the correct molecular weight.

• Quantification strategies:

  • For total TUT1 quantification, consider including all specific bands in densitometry.

  • For isoform-specific analysis, quantify each band separately and report the ratio of isoforms.

  • Always normalize to appropriate loading controls (β-actin, GAPDH, or total protein stains).

This systematic approach will help distinguish biologically relevant TUT1 forms from technical artifacts in Western blot analysis.

What are common pitfalls in TUT1 antibody-based experiments and how can they be addressed?

Researchers should be aware of these common pitfalls when working with TUT1 antibodies:

• Non-specific binding issues:

  • Pitfall: High background or non-specific bands in Western blots.

  • Solution: Increase blocking time/concentration (5% milk or BSA for 2 hours), increase antibody dilution, and include 0.1-0.3% Tween-20 in wash buffers. For particularly problematic antibodies, pre-absorb against cell lysates from TUT1 knockout cells .

• Epitope masking in native conditions:

  • Pitfall: Poor immunoprecipitation efficiency despite good Western blot performance.

  • Solution: Try antibodies targeting different epitopes, particularly N-terminal regions that may be more accessible in the native conformation .

• Fixation-dependent epitope accessibility:

  • Pitfall: Inconsistent immunostaining results across fixation methods.

  • Solution: Systematically compare fixation protocols and include antigen retrieval steps. Document the optimal conditions for each specific TUT1 antibody .

• Cross-reactivity with related proteins:

  • Pitfall: Detecting signals in TUT1 knockout samples.

  • Solution: Validate with multiple antibodies targeting different epitopes, and confirm results with orthogonal methods such as mass spectrometry .

• Batch-to-batch variability:

  • Pitfall: Inconsistent results between antibody lots.

  • Solution: Purchase larger lots for long-term projects, validate each new lot against previous standards, and maintain detailed records of lot numbers and performance.

• Quantification challenges:

  • Pitfall: Difficulty in reliable TUT1 quantification due to variable expression.

  • Solution: Use absolute quantification methods with recombinant protein standards and digital PCR for transcript analysis as complementary approaches.

• RNA-dependent interactions:

  • Pitfall: Loss of protein interactions after RNase treatment.

  • Solution: When studying TUT1 protein interactions, conduct parallel experiments with and without RNase treatment to distinguish RNA-dependent from direct protein-protein interactions.

Addressing these common pitfalls through careful experimental design and validation will significantly improve the reliability of TUT1 antibody-based research.

How can TUT1 antibodies be utilized to investigate RNA processing mechanisms?

TUT1 antibodies enable sophisticated investigations into RNA processing mechanisms through several advanced applications:

• RNA Immunoprecipitation (RIP):

  • TUT1 antibodies can be used to immunoprecipitate TUT1-bound RNAs, followed by RT-qPCR or sequencing to identify direct RNA targets.

  • When performing RIP, use mild crosslinking (0.1% formaldehyde, 10 minutes) to preserve transient RNA-protein interactions.

  • Include RNase inhibitors throughout the protocol to prevent degradation of target RNAs .

• Crosslinking Immunoprecipitation (CLIP):

  • CLIP protocols using TUT1 antibodies can map binding sites at nucleotide resolution by UV-crosslinking RNA-protein complexes.

  • For TUT1 CLIP, optimize UV crosslinking time (typically 150-400 mJ/cm²) based on protein size and abundance.

  • Partial RNase digestion followed by TUT1 immunoprecipitation reveals protected RNA fragments directly bound by TUT1.

• Proximity Ligation Assay (PLA):

  • Combine TUT1 antibodies with antibodies against other RNA processing factors to visualize and quantify protein-protein interactions in situ.

  • This approach has been successfully applied to other RNA-binding proteins and can reveal cell-type or condition-specific TUT1 interactions .

• Immunofluorescence combined with RNA-FISH:

  • Co-localization of TUT1 protein (detected by IF) with specific RNAs (detected by FISH) can provide spatial context for TUT1-RNA interactions.

  • This approach can reveal whether TUT1 associates with particular RNA species in specific subcellular compartments.

• Chromatin Immunoprecipitation (ChIP):

  • As TUT1 functions in RNA processing, ChIP using TUT1 antibodies can reveal associations with nascent transcripts at active genes.

  • This approach can help distinguish co-transcriptional versus post-transcriptional roles of TUT1.

• Pulse-chase labeling combined with immunoprecipitation:

  • Metabolic labeling of RNA (e.g., with 4SU) followed by TUT1 immunoprecipitation can reveal the dynamics of TUT1-RNA interactions.

  • This approach can help determine whether TUT1 preferentially binds newly synthesized or mature RNAs.

These advanced applications leverage the specificity of well-validated TUT1 antibodies to provide mechanistic insights into RNA processing pathways.

What are emerging applications of TUT1 antibodies in disease-related research?

TUT1 antibodies are increasingly valuable in disease-related research, particularly in areas where RNA processing dysregulation contributes to pathogenesis:

• Cancer research applications:

  • TUT1 expression analysis in tumor tissues using validated antibodies for IHC can reveal correlations with patient outcomes and treatment responses .

  • Changes in TUT1 subcellular localization (detected by IF) may serve as markers for altered RNA processing in cancer cells.

  • Immunoprecipitation followed by mass spectrometry can identify cancer-specific TUT1 interaction partners that may represent novel therapeutic targets.

• Neurodegenerative disease investigations:

  • Similar to studies on TIA1 in ALS and FTD, TUT1 antibodies can be used to investigate potential roles in RNA processing dysregulation in neurodegeneration .

  • Co-localization studies with stress granule markers can reveal whether TUT1 participates in pathological RNA granule formation.

  • Phosphorylation-specific TUT1 antibodies could identify disease-associated post-translational modifications.

• Viral infection studies:

  • TUT1's role in RNA processing makes it relevant to viral infection biology, where antibodies can be used to track changes in TUT1 localization and activity during infection.

  • Similar to approaches used for virus-like particles, TUT1 antibodies can help characterize RNA-protein complexes formed during viral replication .

• Developmental biology applications:

  • TUT1 antibodies can track expression changes during development, potentially revealing stage-specific roles in RNA processing.

  • Tissue-specific expression patterns detected by IHC may identify previously unknown functions in specific developmental contexts.

• Drug development and therapeutic target validation:

  • High-throughput immunoassays using TUT1 antibodies can screen compounds that modulate TUT1 expression or activity.

  • Target engagement studies can confirm whether candidate drugs affect TUT1 in predicted ways within cellular contexts.

• Biomarker development:

  • Quantitative assays using TUT1 antibodies (e.g., ELISA, multiplexed immunoassays) could potentially identify disease-associated changes in TUT1 expression or modification patterns.

These emerging applications highlight the importance of well-validated, application-specific TUT1 antibodies in translational research contexts.

How can researchers integrate TUT1 antibody data with other omics approaches?

Integrating TUT1 antibody-derived data with other omics approaches can provide comprehensive insights into RNA processing mechanisms:

• Multi-omics integration strategies:

  Omics Approach	TUT1 Antibody Application	Integration Benefit
  Transcriptomics (RNA-seq)	RIP-seq with TUT1 antibodies	Identifies direct RNA targets with transcriptome-wide changes after TUT1 manipulation
  Proteomics	IP-MS with TUT1 antibodies	Maps TUT1 protein interaction network and correlates with expression changes
  Genomics	ChIP-seq with TUT1 antibodies	Links chromatin association to RNA processing events
  Epitranscriptomics	TUT1 IP followed by RNA modification analysis	Connects TUT1 binding to specific RNA modifications
  Single-cell analyses	IF with TUT1 antibodies in scRNA-seq workflows	Relates protein-level heterogeneity to transcriptional states

• Computational integration approaches:

  • Network analysis can integrate TUT1 protein interactions (from IP-MS) with RNA targets (from RIP-seq) to build comprehensive functional networks.

  • Machine learning algorithms can identify patterns in multi-omics data that predict TUT1 binding sites or functional impacts.

  • Pathway enrichment analyses combining proteomics and transcriptomics data can reveal biological processes influenced by TUT1 activity.

• Temporal integration:

  • Time-course experiments using TUT1 antibodies can be integrated with dynamic transcriptomics to establish cause-effect relationships in RNA processing.

  • Pulse-chase experiments combined with omics approaches can reveal the kinetics of TUT1-mediated RNA modifications.

• Spatial integration:

  • TUT1 immunofluorescence data can be integrated with spatial transcriptomics to correlate subcellular localization with region-specific RNA processing events.

  • Proximity labeling approaches (BioID, APEX) with TUT1 fusion proteins can identify spatially-restricted interaction partners for integration with other spatial omics data.

• Functional validation integration:

  • Findings from omics integration should be validated using targeted approaches with TUT1 antibodies (e.g., validating predicted RNA targets with RIP-qPCR).

  • CRISPR screens can be integrated with TUT1 antibody-based assays to identify factors affecting TUT1 function or localization.

This multi-layered integration approach can provide unprecedented insights into TUT1's role in RNA processing and cellular function, revealing regulatory mechanisms and potential therapeutic targets.

How might new antibody technologies enhance TUT1 research in the coming years?

Emerging antibody technologies promise to revolutionize TUT1 research through several innovations:

• Single-domain antibodies and nanobodies:

  • Smaller antibody formats may access epitopes in TUT1 that are sterically hindered for conventional antibodies, potentially revealing new functional insights.

  • Their reduced size allows better penetration into subcellular compartments, improving the resolution of TUT1 localization studies.

  • These formats are particularly valuable for live-cell imaging of TUT1 dynamics due to their ability to function in reducing intracellular environments .

• Recombinant antibody technologies:

  • Phage display-derived recombinant TUT1 antibodies offer improved batch-to-batch reproducibility compared to traditional polyclonal antibodies.

  • Site-specific modifications of recombinant antibodies enable precise control over conjugation chemistry for specialized applications.

  • Antibody engineering approaches can optimize affinity and specificity for challenging TUT1 epitopes .

• Intrabodies and chromobodies:

  • Engineered antibody fragments expressed intracellularly can track TUT1 in living cells without fixation artifacts.

  • Fusion of fluorescent proteins to TUT1-specific antibody fragments (chromobodies) allows real-time monitoring of TUT1 dynamics during RNA processing events.

• Epitope-specific modification sensors:

  • Development of antibodies specifically recognizing post-translationally modified forms of TUT1 (phosphorylated, ubiquitinated, etc.) will enable tracking of TUT1 regulation in response to cellular signals.

  • Conformation-specific antibodies could distinguish between active and inactive TUT1 states.

• Multiplexed antibody technologies:

  • Advanced multiplexing methods (Cytof, CODEX, etc.) will allow simultaneous detection of TUT1 alongside dozens of other proteins in single cells.

  • These approaches will reveal how TUT1 function correlates with broader cellular states and signaling networks.

• In situ antibody-based proximity labeling:

  • TUT1 antibodies conjugated to proximity labeling enzymes (APEX, BioID) can map the proximal proteome specifically at TUT1 localization sites.

  • This approach will reveal microenvironment-specific interactions that may be diluted in whole-cell analyses.

These technological advances will address current limitations in studying TUT1 biology and enable more sophisticated investigations of its roles in RNA processing and cellular function.

What standardization efforts are needed to improve reproducibility in TUT1 antibody research?

To enhance reproducibility in TUT1 antibody research, several key standardization efforts are needed:

• Comprehensive antibody validation standards:

  • Implement multi-method validation approaches similar to those used for TIA1 antibodies, including genetic knockout controls, peptide competition, cross-platform validation, and cross-antibody comparison .

  • Establish minimum validation requirements before antibodies are used in critical experiments, including specificity testing in the exact experimental system and application intended.

  • Create shared repositories of validation data accessible to the research community.

• Reporting standards for methods sections:

  • Require detailed reporting of antibody catalog numbers, lot numbers, validation methods, dilution factors, incubation conditions, and blocking reagents.

  • Implement standardized nomenclature for TUT1 domains and epitopes to clarify which region each antibody targets.

  • Encourage sharing of complete protocols through protocol repositories to enable precise replication.

• Reference materials development:

  • Establish community-endorsed positive and negative control cell lines or tissues for TUT1 detection.

  • Develop calibrated recombinant TUT1 protein standards for quantitative applications.

  • Create reference images for expected TUT1 staining patterns in commonly used cell types.

• Interlaboratory studies and proficiency testing:

  • Organize ring trials where multiple laboratories test the same TUT1 antibodies using standardized protocols.

  • Identify sources of variability and establish best practices to minimize these factors.

  • Develop consensus guidelines for interpreting TUT1 antibody-based experimental results.

• Application-specific optimization guidelines:

  • Create detailed protocols optimized for each application (WB, IHC, IF, IP, etc.) with specific recommendations for TUT1 detection.

  • Establish quantitative metrics for assessing antibody performance in each application.

  • Develop troubleshooting decision trees for common problems encountered in TUT1 antibody applications.

• Data sharing initiatives:

  • Establish centralized databases for sharing raw TUT1 antibody validation data, including negative results.

  • Create platforms for researchers to report their experiences with specific TUT1 antibodies.

  • Develop machine-readable formats for antibody-related metadata to facilitate computational integration.

Implementation of these standardization efforts would significantly enhance reproducibility and accelerate progress in TUT1 research by reducing time spent troubleshooting and validating reagents.